Navigating Non-Product Software Validation in GxP Environments

Yashaswini Maregowda

and

May 11, 2026

Table of Contents

1. Introduction
2. What Is Non-Product Software?
3. Overlapping Common Expectations
4. Conclusion

1. Introduction

When life sciences organizations talk about software validation, the conversation always gravitates toward product software, embedded device firmware, or clinical trial software that touches the regulated product directly.

There is an equally important category of GxP software that underpins every regulated operation: non-product software. It includes laboratory information management systems (LIMS), quality management systems (QMS), document management platforms, training systems, and AI-driven analytical tools. Even without being part of the product itself, this software must still be validated.

2. What Is Non-Product Software?

Non-product software is any software used in a GxP-regulated environment that does not become part of the product and is not embedded in a medical device. Despite this distinction, it directly influences product quality, patient safety, and data integrity, which is precisely why it falls within the scope of regulatory oversight.

Examples include:

• Quality Management Systems (QMS): CAPA management, deviation tracking, document control, training management, audit management platforms
• Laboratory Systems: LIMS, electronic lab notebooks (ELN), chromatography data systems (CDS)
• Manufacturing Systems: MES, SCADA, building management systems, batch record systems, ERP modules governing GxP operations
• Regulatory & Submission Support Tools: AI/ML models used to analyze manufacturing data, generate statistical summaries, or support regulatory submissions
• Infrastructure & Supporting Software: Backup and restore systems, access management platforms, audit trail repositories, archival systems

3. Overlapping Common Expectations

The 10 Common Expectations

1. Risk-Based Validation & Classification
   Stratify validation effort by patient safety, data integrity, and product quality impact.

2. Requirements Management & Lifecycle Traceability
   Documented URS linked to test evidence across the full lifecycle.

3. Change Control & Impact Assessment
   Assess changes for impact on performance and data integrity, scaled to risk.

4. Audit Trail & Electronic Records Integrity
   Secure, computer-generated audit trails for all GxP electronic records.

5. Testing Strategy Proportionate to Risk
   Scripted, exploratory, and statistical testing justified by risk assessment.

6. Document Lifecycle & Version Control
   Controlled, complete, and current validation packages with full traceability.

7. Role-Based Access Control (RBAC)
   Role-based, documented, and auditable access frameworks for all systems.

8. Incident Management & CAPA
   Investigate and remediate software and AI failures within the quality system.

9. Vendor & Supplier Qualification
   Risk-prioritized supplier evaluation covering quality systems and data governance.

10. Periodic Review & Continued State of Control
    Ongoing monitoring with defined frequency, metrics, and escalation paths.

4. Conclusion

The four frameworks examined here, FDA CSA, the FDA AI Guidance for Drugs and Biologics, GAMP5, and ISO 13485, converge on the same core expectations: risk-based classification, requirements traceability, change control, data integrity, and periodic review. Organizations do not need four compliance programs. They need one program built on this shared architecture, with extensions where a specific framework imposes additional requirements. The goal is not to collect validation documents. The goal is to ensure that every non-product software system in your GxP environment reliably does what it is supposed to do, that you can prove it, and that you will know when it stops.